Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.

Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK.

Leukemia. 2010 Mar;24(3):563-72. doi: 10.1038/leu.2009.281. Epub 2010 Jan 14.


Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.

Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M.

Blood. 2005 Mar 15;105(6):2436-42. Epub 2004 Nov 9.


Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.

Takahashi S, Rousseau RF, Yotnda P, Mei Z, Dotti G, Rill D, Hurwitz R, Marini F, Andreeff M, Brenner MK.

Hum Gene Ther. 2001 Apr 10;12(6):659-70.


Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.

Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, Popat U, Marini F, Andreeff M, Brenner MK, Rousseau RF.

Hum Gene Ther. 2003 Apr 10;14(6):545-59.


Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.

Giannopoulos K, Dmoszynska A, Kowal M, Rolinski J, Gostick E, Price DA, Greiner J, Rojewski M, Stilgenbauer S, Döhner H, Schmitt M.

Leukemia. 2010 Apr;24(4):798-805. doi: 10.1038/leu.2010.29. Epub 2010 Mar 11.


Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.

Giannopoulos K, Li L, Bojarska-Junak A, Rolinski J, Dmoszynska A, Hus I, Greiner J, Renner C, Döhner H, Schmitt M.

Int J Oncol. 2006 Jul;29(1):95-103.


The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia.

Giannopoulos K, Mertens D, Bühler A, Barth TF, Idler I, Möller P, Kröber A, Greiner J, Chocholska S, Dmoszyñska A, Roliñski J, Döhner H, Stilgenbauer S, Schmitt M.

Leukemia. 2009 Mar;23(3):519-27. doi: 10.1038/leu.2008.338. Epub 2008 Dec 18.


Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.

Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos K, Dmoszyńska A, Roliński J.

Leukemia. 2008 May;22(5):1007-17. doi: 10.1038/leu.2008.29. Epub 2008 Mar 6.


Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.

Tabarkiewicz J, Giannopoulos K.

Transplant Proc. 2010 Oct;42(8):3293-6. doi: 10.1016/j.transproceed.2010.07.022. Review.


Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.

Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6916-23.


Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.

Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein NL, Imrie K, Spaner DE.

Clin Cancer Res. 2003 May;9(5):1656-65.


A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.

Kronenberger K, Nössner E, Frankenberger B, Wahl U, Dreyling M, Hallek M, Mocikat R.

J Immunother. 2008 Oct;31(8):723-30. doi: 10.1097/CJI.0b013e318183af26.


Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.

Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner CM.

Blood. 2005 Feb 15;105(4):1566-73. Epub 2004 Oct 7.


Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.

Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK.

Cytotherapy. 2011 Oct;13(9):1128-39. doi: 10.3109/14653249.2011.592523. Epub 2011 Jul 12.


Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszyńska A, Schmitt M.

Leukemia. 2005 Sep;19(9):1621-7.


Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY.

Blood. 2005 Nov 15;106(10):3515-23. Epub 2005 Aug 4.


Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate.

Suresh K, Fraser G, Scheid E, Leber B, Gauldie J, Foley R.

Leuk Lymphoma. 2006 Feb;47(2):297-306.


CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.

Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA, van Oers MH, Eldering E.

Br J Haematol. 2004 Nov;127(4):404-15.


Supplemental Content

Support Center